Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Lancet Respiratory Medicine,The - Tập 10 - Trang 1019-1028 - 2022
Yuankai Shi1, Gongyan Chen2, Xiang Wang3, Yunpeng Liu4, Lin Wu5, Yanrong Hao6, Chunling Liu7, Shuyang Zhu8, Xiaodong Zhang9, Yuping Li10, Jiwei Liu11, Lejie Cao12, Ying Cheng13, Hui Zhao14, Shucai Zhang15, Aimin Zang16, Jiuwei Cui17, Jian Feng18, Nong Yang19, Fei Liu20
1Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
3Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China
4Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
5Thoracic Medicine Department II, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
6Department of Medical Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
7Department of Pulmonary Medicine, Cancer Hospital of Xinjiang Medical University, Urumqi, China
8Department of Respiratory Medicine, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China
9Department of Medical Oncology, Nantong Cancer Hospital, Nantong, China
10Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
11Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
12Department of Respiratory Medicine, The First Affiliated Hospital of USTC, Hefei, China
13Department of Oncology, Jilin Cancer Hospital, Changchun, China
14Department of Respiratory and Critical Care Medicine, The Second Hospital of Anhui University, Hefei, China
15Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Oncology Institute, Beijing, China
16Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China
17Cancer Center, the First Hospital of Jilin University, Changchun, China
18Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
19Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
20Shanghai Allist Pharmaceuticals, Shanghai, China

Tài liệu tham khảo

Marchetti, 2005, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment, J Clin Oncol, 23, 857, 10.1200/JCO.2005.08.043 Shi, 2014, A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), J Thorac Oncol, 9, 154, 10.1097/JTO.0000000000000033 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X Shi, 2017, First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study, Ann Oncol, 28, 2443, 10.1093/annonc/mdx359 Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3327, 10.1200/JCO.2012.44.2806 Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246 Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, 4, 1046, 10.1158/2159-8290.CD-14-0337 Ramalingam, 2020, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC, N Engl J Med, 382, 41, 10.1056/NEJMoa1913662 Reungwetwattana, 2018, CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer, J Clin Oncol, 10.1200/JCO.2018.78.3118 Shi, 2020, Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation, J Thorac Oncol, 15, 1015, 10.1016/j.jtho.2020.01.010 Shi, 2021, Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study, Lancet Respir Med, 9, 829, 10.1016/S2213-2600(20)30455-0 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Bergman, 1994, The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials, Eur J Cancer, 30A, 635, 10.1016/0959-8049(94)90535-5 Cheng, 2021, Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study, Target Oncol, 16, 165, 10.1007/s11523-021-00794-6 Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137 Lu, 2021, Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm), Proc Am Soc Clin Oncol, 39 Wu, 2014, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, 15, 213, 10.1016/S1470-2045(13)70604-1 Wu, 2015, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study, Ann Oncol, 26, 1883, 10.1093/annonc/mdv270 Papadimitrakopoulou, 2018, Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study, Ann Oncol, 29, 10.1093/annonc/mdy424.064 Lu, 2021, Final results of APOLLO study: overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), Ann Oncol, 32, S962, 10.1016/j.annonc.2021.08.1813 Han, 2021, Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins), Ann Oncol, 32, S964, 10.1016/j.annonc.2021.08.1815 Deeks, 2021, Furmonertinib: first Approval, Drugs, 81, 1775, 10.1007/s40265-021-01588-w Lu, 2021, D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study, Cancer Res, 81 Nagasaka, 2021, Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC, J Thorac Oncol, 16, 740, 10.1016/j.jtho.2020.11.028 Yang, 2017, Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis, Int J Cancer, 140, 2805, 10.1002/ijc.30691
Thông tin
Thông tin xuất bản

Lancet Respiratory Medicine,The

Tập 10

1019-1028

Thông tin tác giả